Coronavirus Outbreak: Pidilite Industries to contribute Rs 25 cr towards Covid-19 relief funds

Pidilite Industries on Monday said it will contribution of Rs 25 crore towards relief funds to fight the coronavirus pandemic

Press Trust of India April 13, 2020 14:32:27 IST
Coronavirus Outbreak: Pidilite Industries to contribute Rs 25 cr towards Covid-19 relief funds

Mumbai: Pidilite Industries on Monday said it will contribution of Rs 25 crore towards relief funds to fight the coronavirus pandemic.

Coronavirus Outbreak Pidilite Industries to contribute Rs 25 cr towards Covid19 relief funds

Representational image. Reuters

This contribution will be made to the central as well as other emergency state relief funds, the company said in a statement.

Click here to follow LIVE updates on coronavirus outbreak

Pidilite Industries Ltd Managing Director Bharat Puri said, “We stand in solidarity with the people of India and our government''s efforts to overcome this unprecedented pandemic."

He further said that the company will continue to care for the health and well-being of its partners and employees while constructively supporting the various relief efforts announced by the government.

Updated Date:

also read

Dengue cases climb in West Bengal, 840 new infections in run-up to festival
India

Dengue cases climb in West Bengal, 840 new infections in run-up to festival

Most of the cases have been reported from North 24 Parganas, Howrah, Kolkata, Hooghly, Murshidabad, South 24 Parganas, Jalpaiguri and Darjeeling districts

COVID-19: Active Covid cases in India rise to 46,342
Health

COVID-19: Active Covid cases in India rise to 46,342

The active cases comprise 0.10 per cent of the total infections, while the national COVID-19 recovery rate increased to 98.71 per cent.

Moderna will not bow to China’s coercion, refuses to give COVID-19 vaccine recipe over ‘safety’ concerns
World

Moderna will not bow to China’s coercion, refuses to give COVID-19 vaccine recipe over ‘safety’ concerns

China hasn’t approved any foreign vaccine and has been insisting on sharing the technology behind the Moderna vaccine as a prerequisite for allowing its sale in the country